


EXIMIOUS AND THE EXPOSOME

EXIMIOUS is a European research project that aims to develop a new way of assessing the human exposome, to better understand the factors that lead to exposure-related immune effects at different stages of people's lives.



By unravelling the connections between our immune system, our genetic material and the environment, EXIMIOUS will help put in place the right preventive actions and policies to safeguard the individual, group and population well-being.

BENEFITS FOR SOCIETY

Identify the most critical types of exposure and the individuals/groups bearing the highest risk in order to put in place the right preventive actions and policies.

Help improve the quality of life of patients with autoimmune diseases, by providing the means to assign a cause for their illness, improving coping strategies.

Alleviate medical costs through improved diagnosis and more targeted treatment.

WANT TO LEARN MORE?

Follow us:



EXIMIOUS_H2020



info@eximious-h2020.eu

www.eximious-h2020.eu

A COHORT STUDY

The EXIMIOUS partners will collect clinical data (e.g. blood and urine samples), socio-economic data as well as information on the environmental exposures and the health status of the immune system, of participants from several cohorts—covering the entire lifespan, including prenatal life.

GENERAL POPULATION & BIRTH COHORTS

- The LifeLines Cohort Study – The Netherlands
- ENVIRonAGE birth cohort – Belgium
- DOC*X cohort – Denmark
- DOC*X generation – Denmark



OCCUPATIONAL COHORTS

- Waste workers – Denmark
- Park workers – Spain
- Workers exposed to mineral dust and organic solvents – Romania



DISEASE COHORTS

- Systemic Sclerosis (SS) – Belgium
- Rheumatoid Arthritis (RA) – Belgium
- Sarcoidosis – Belgium
- Systemic Lupus Erythematosus (SLE) – Belgium
- Hypersensitivity Pneumonitis (HP) – Spain





EUROPE-WIDE COLLABORATION

15 partners

7 countries across Europe

5 years (01.01.2020 - 31.12.2024)

1 of 9 projects within the European Human Exposome Network (EHEN)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 874707.